Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 42.53% | 51.47% | 59.73% | 73.58% | 440.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.53% | 51.47% | 59.73% | 73.58% | 440.80% |
| Cost of Revenue | 27.77% | 51.76% | 85.08% | 112.85% | 536.04% |
| Gross Profit | 44.11% | 51.45% | 57.41% | 70.14% | 432.30% |
| SG&A Expenses | 27.31% | 29.24% | 45.79% | 67.47% | 102.90% |
| Depreciation & Amortization | 0.27% | 0.27% | 0.28% | 11.90% | 53.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.71% | 43.96% | 60.37% | 72.09% | 101.17% |
| Operating Income | -38.01% | -34.76% | -61.08% | -70.59% | -4.28% |
| Income Before Tax | -20.50% | -55.22% | -69.63% | -90.85% | -27.33% |
| Income Tax Expenses | -91.15% | -125.29% | -151.10% | -162.79% | -- |
| Earnings from Continuing Operations | -20.05% | -54.07% | -67.28% | -86.73% | -27.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.05% | -54.07% | -67.28% | -86.73% | -27.84% |
| EBIT | -38.01% | -34.76% | -61.08% | -70.59% | -4.28% |
| EBITDA | -38.85% | -35.62% | -63.34% | -73.06% | -2.97% |
| EPS Basic | -15.29% | -44.44% | -52.20% | -67.92% | -13.57% |
| Normalized Basic EPS | -30.95% | -24.35% | -41.01% | -48.09% | 7.75% |
| EPS Diluted | -15.29% | -44.44% | -52.20% | -67.92% | -13.57% |
| Normalized Diluted EPS | -30.95% | -24.35% | -41.01% | -48.09% | 7.75% |
| Average Basic Shares Outstanding | 5.51% | 7.13% | 9.90% | 10.58% | 11.74% |
| Average Diluted Shares Outstanding | 5.51% | 7.13% | 9.90% | 10.58% | 11.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
